Recent Updates
Recently added Catalysts
NPCE Positive Sentiment Score: 70/100

NeuroPace to Report Second Quarter 2023 Financial Results on August 8, 2023

Key Takeaway: NeuroPace, Inc. is set to report its financial results for the second quarter of 2023 on August 8, 2023. The report will follow a conference call scheduled for 1:30 p.m. Pacific Time, which will be accessible to investors both live and via a recorded archive. NeuroPace is dedicated to improving the lives of individuals with epilepsy, particularly through its innovative RNS System, designed to deliver personalized treatment for seizure management.

Market Sentiment Analysis

POSITIVE FACTORS

  • NeuroPace is focused on transforming the lives of people with epilepsy.
  • The RNS System offers personalized, real-time treatment for seizures.
  • The upcoming financial results may signal ongoing progress and investor interest.

Full Press Release Details

MOUNTAIN VIEW, Calif., July 18, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the second quarter of 2023 after market close on Tuesday August 8, 2023. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at https://edge.media-server.com/mmc/p/uk5rzkfn. Individuals interested in participating in the call via telephone may access the call by dialing +1-888-886-7786 and referencing Conference ID 95685732. The webcast will be archived on the company’s investor relations website at https://investors.neuropace.com/news-and-events/events and will be available for replay for at least 90 days after the event.
About NeuroPace, Inc.
Based in Mountain View, Calif., NeuroPace is a commercial-stage medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.

Frequently Asked Questions

When will NeuroPace report its Q2 2023 financial results?

NeuroPace will report its Q2 2023 financial results on August 8, 2023.

How can I listen to the NeuroPace conference call?

You can listen via live or archived webcast at NeuroPace's event page.

What is NeuroPace's focus as a medical device company?

NeuroPace focuses on transforming lives of people with epilepsy through innovative devices.

What is the RNS System by NeuroPace?

The RNS System is a brain-responsive platform for treating drug-resistant epilepsy.

How long will the conference replay be available?

The conference replay will be available for at least 90 days after the event.

Last updated: Jul 18, 2023